Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
In some embodiments, the invention relates to crystalline solid forms, including hydrates, polymorphs, and salt forms, of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention relates to amorphous solid forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. In some embodiments, the invention also relates to pharmaceutical compositions containing the solid forms, and methods for treating conditions or disorders by administering to a subject a pharmaceutical composition that includes the forms, including pharmaceutical compositions and methods for overcoming the effects of acid reducing agents.
1. A solid pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and 95-105 mg of a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide characterized by a reflection X-ray powder diffraction pattern comprising peaks at 6.4° ±0.2° 2θ, 8.6°±0.2° 2θ, 10.5° ±0.2° 2θ, 11.6° ±0.2° 2θ and 15.7° ±0.2° 2θ.
2. The solid pharmaceutical composition of claim 1 , wherein the reflection X-ray powder diffraction pattern of the crystal form further comprises peaks at 10.9° ±0.2° 2θ, 12.7° ±0.2° 2θ, 13.4° ±0.2° 2θ, 14.3° ±0.2° 2θ, 14.9° ±0.2° 2θ and 18.2° ±0.2° 2θ.
3. The solid pharmaceutical composition of claim 2 , wherein the reflection X-ray powder diffraction pattern of the crystal form further comprises one or more peaks selected from the group consisting of 11.3° ±0.2° 2θ, 15.1° ±0.2° 2θ, 15.7° ±0.2° 2θ, 16.1° ±0.2° 2θ, 17.3° ±0.2° 2θ, 19.2° ±0.2° 2θ, 19.4° ±0.2° 2θ, 19.8° ±0.2° 2θ, 20.7° ±0.2° 2θ, 21.1° ±0.2° 2θ, 21.4° ±0.2° 2θ, 21.6° ±0.2° 2θ, 21.9° ±0.2° 2θ, 22.6° ±0.2° 2θ, 23.3° ±0.2° 2θ, 23.6° ±0.2° 2θ, 24.9° ±0.2° 2θ, 25.2° ±0.2° 2θ, 25.4° ±0.2° 2θ, 25.7° ±0.2° 2θ, 26.1° ±0.2° 2θ, 26.4° ±0.2° 2θ, 26.8° ±0.2° 2θ, 26.9° ±0.2° 2θ, 27.7° ±0.2° 2θ, 28.6° ±0.2° 2θ, 29.1° ±0.2° 2θ, 29.4° ±0.2° 2θ, 30.1° ±0.2° 2θ, 30.5° ±0.2° 2θ, 31.7° ±0.2° 2θ, 31.9° ±0.2° 2θ, 32.2° ±0.2° 2θ, 32.6° ±0.2° 2θ, 33.1° ±0.2° 2θ, 33.4° ±0.2° 2θ, 34.5° ±0.2° 2θ, 35.9° ±0.2° 2θ, 36.1° ±0.2° 2θ, 36.8° ±0.2° 2θ, 37.4° ±0.2° 2θ, 38.1° ±0.2° 2θ, 38.9° ±0.2° 2θ and 39.5° ±0.2° 2θ.
4. The solid pharmaceutical composition of claim 1 , wherein the crystal form is further characterized by a Raman spectrum comprising peaks at 1620 ±4 cm −1 , 1609 ±4 cm −1 , 1547 ±4 cm −1 , 1514 ±4 cm −1 and 1495 ±4 cm −1 .
5. The solid pharmaceutical composition of claim 4 , wherein the Raman spectrum of the crystal form further comprises one or more peaks selected from the group consisting of 1680 ±4 cm −1 , 1574 ±4 cm −1 , 1454 ±4 cm −1 , 1433 ±4 cm −1 , 1351 ±4 cm −1 , 1312 ±4 cm −1 , 1255 ±4 cm −1 , 1232 ±4 cm −1 , 1187 ±4 cm −1 , 1046 ±4 cm −1 , 995 ±4 cm −1 , 706 ±4 cm −1 , 406 ±4 cm −1 and 280 ±4 cm −1 .
6. The solid pharmaceutical composition of claim 1 , wherein the crystal form is further characterized by an infrared spectrum comprising peaks at 1621 ±4 cm −1 , 1608 ±4 cm −1 , 1403 ±4 cm −1 , 1303 ±4 cm −1 and 764 cm −1 ±4 cm −1 .
7. The solid pharmaceutical composition of claim 6 , wherein the infrared spectrum of the crystal form further comprises one or more peaks selected from the group consisting of 3367 ±4 cm −1 , 3089 ±4 cm −1 , 2246 ±4 cm −1 , 1682 ±4 cm −1 , 1574 ±4 cm −1 , 1514 ±4 cm −1 , 1504 ±4 cm −1 , 1454 ±4 cm −1 , 1428 ±4 cm −1 , 1345 ±4 cm −1 , 1248 ±4 cm −1 , 1194 ±4 cm −1 , 1177 ±4 cm −1 , 1149 ±4 cm −1 , 1109 ±4 cm −1 , 1049 ±4 cm −1 , 1023 ±4 cm −1 , 1003 ±4 cm −1 , 947 ±4 cm −1 , 900 ±4 cm −1 , 858 ±4 cm −1 , 842 ±4 cm −1 , 816 ±4 cm −1 , 734 ±4 cm −1 , 729 ±4 cm −1 , 701 ±4 cm −1 , 689 ±4 cm −1 , 665 ±4 cm −1 , 623 ±4 cm −1 and 612 ±4 cm −1 .
8. The solid pharmaceutical composition of claim 1 , wherein the crystal form is further characterized by a Raman spectrum comprising peaks at 1620 ±4 cm −1 , 1609 ±4 cm −1 , 1547 ±4 cm −1 , 1514 ±4 cm −1 and 1495 ±4 cm −1 ; and by an infrared spectrum comprising peaks at 1621 ±4 cm −1 , 1608 ±4 cm −1 , 1403 ±4 cm −1 , 1303 ±4 cm −1 and 764 ±4 cm −1 .
9. The solid pharmaceutical composition of claim 8 , wherein the crystal form is a crystalline anhydrate.
10. The solid pharmaceutical composition of claim 9 , wherein the solid pharmaceutical composition is a capsule.
11. The solid pharmaceutical composition of claim 10 , wherein the peaks of the reflection X-ray powder diffraction pattern are present when the reflection X-ray powder diffraction is carried out using Cu-K α radiation.
12. The solid pharmaceutical composition of claim 11 , wherein the peaks of the reflection X-ray powder diffraction pattern are present when the reflection X-ray powder diffraction is carried out using a Bruker D8 Advance powder X-ray diffractometer equipped with a LynxEye detector and operating in Bragg-Brentano reflection geometry mode, a tube voltage of 40 kV and current of 40 mA, a variable divergence slit with a 3° window, a step size of 0.02° 2θ, a sample rotation of 0.5 revolution per second and a step time of 37 seconds.
13. The solid pharmaceutical composition of claim 1 , wherein the solid pharmaceutical composition comprises 100 mg of a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide.
14. A method for inhibiting Bruton's tyrosine kinase activity in a human, comprising orally administering to said human twice daily a solid pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and 95-105 mg of a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide characterized by a reflection X-ray powder diffraction pattern comprising peaks at 6.4° ±0.2° 2θ, 8.6° ±0.2° 2θ, 10.5° ±0.2° 2θ, 11.6° ±0.2° 2θ and 15.7° ±0.2° 2θ.
15. The method of claim 14 , wherein the reflection X-ray powder diffraction pattern of the crystal form further comprises peaks at 10.9° ±0.2° 2θ, 12.7° ±0.2° 2θ, 13.4° ±0.2° 2θ, 14.3° ±0.2° 2θ, 14.9° ±0.2° 2θ and 18.2° ±0.2° 2θ.
16. The method of claim 15 , wherein the reflection X-ray powder diffraction pattern of the crystal form further comprises one or more peaks selected from the group consisting of 11.3° ±0.2° 2θ, 15.1° ±0.2° 2θ, 15.7° ±+0.2° 2θ, 16.1° ±0.2° 2θ, 17.3° ±0.2° 2θ, 19.2° ±0.2° 2θ, 19.4° ±0.2° 2θ, 19.8° ±0.2° 2θ, 20.7° ±+0.2° 2θ, 21.1° ±0.2° 2θ, 21.4° ±0.2° 2θ, 21.6° ±0.2° 2θ, 21.9° ±0.2° 2θ, 22.6° ±0.2° 2θ, 23.3° ±0.2° 2θ, 23.6° ±0.2° 2θ, 24.9° ±0.2° 2θ, 25.2° ±0.2° 2θ, 25.4° ±0.2° 2θ, 25.7° ±0.2° 2θ, 26.1° ±0.2° 2θ, 26.4° ±0.2° 2θ, 26.8° ±0.2° 2θ, 26.9° ±0.2° 2θ, 27.7° ±0.2° 2θ, 28.6° ±0.2° 2θ, 29.1° ±0.2° 2θ, 29.4° ±0.2° 2θ, 30.1° ±0.2° 2θ, 30.5° ±0.2° 2θ, 31.7° ±0.2° 2θ, 31.9° ±0.2° 2θ, 32.2° ±0.2° 2θ, 32.6° ±0.2° 2θ, 33.1° ±0.2° 2θ, 33.4° ±0.2° 2θ, 34.5° ±0.2° 2θ, 35.9° ±0.2° 2θ, 36.1° ±0.2° 2θ, 36.8° ±0.2° 2θ, 37.4° ±0.2° 2θ, 38.1° ±0.2° 2θ, 38.9° ±0.2° 2θ and 39.5° ±0.2° 2θ.
17. The method of claim 14 , wherein the crystal form is further characterized by a Raman spectrum comprising peaks at 1620 ±4 cm −1 , 1609 ±4 cm −1 , 1547 ±4 cm −1 , 1514 ±4 cm −1 and 1495 ±4 cm −1 .
18. The method of claim 17 , wherein the Raman spectrum of the crystal form further comprises one or more peaks selected from the group consisting of 1680 ±4 cm −1 , 1574 ±4 cm −1 , 1454 ±4 cm −1 , 1433 ±4 cm −1 , 1351 ±4 cm −1 , 1312 ±4 cm −1 , 1255 ±4 cm −1 , 1232 ±4 cm −1 , 1187 ±4 cm −1 , 1046 ±4 cm −1 , 995 ±4 cm −1 , 706 ±4 cm −1 , 406 ±4 cm −1 and 280 ±4 cm −1 .
19. The method of claim 14 , wherein the crystal form is further characterized by an infrared spectrum comprising peaks at 1621 ±4 cm −1 , 1608 ±4 cm −1 , 1403 ±4 cm −1 , 1303 ±4 cm −1 and 764 ±4 cm −1 .
20. The method of claim 19 , wherein the infrared spectrum of the crystal form further comprises one or more peaks selected from the group consisting of 3367 ±4 cm −1 , 3089 ±4 cm −1 , 2246 ±4 cm −1 , 1682 ±4 cm −1 , 1574 ±4 cm −1 , 1514 ±4 cm −1 , 1504 ±4 cm −1 , 1454 ±4 cm −1 , 1428 ±4 cm −1 , 1345 ±4 cm −1 , 1248 ±4 cm −1 , 1194 ±4 cm −1 , 1177 ±4 cm −1 , 1149 ±4 cm −1 , 1109 ±4 cm −1 , 1049 ±4 cm −1 , 1023 ±4 cm −1 , 1003 ±4 cm −1 , 947 ±4 cm −1 , 900 ±4 cm −1 , 858 ±4 cm −1 , 842 ±4 cm −1 , 816 ±4 cm −1 , 734 ±4 cm −1 , 729 ±4 cm −1 , 701 ±4 cm −1 , 689 ±4 cm −1 , 665 ±4 cm −1 , 623 ±4 cm −1 and 612 ±4 cm −1 .
21. The method of claim 14 , wherein the crystal form is further characterized by a Raman spectrum comprising peaks at 1620 cm −1 , 1609 cm −1 , 1547 cm −1 , 1514 cm −1 and 1495 cm −1 ±4 cm −1 ; and by an infrared spectrum comprising peaks at 1621 cm −1 , 1608 cm −1 , 1403 cm −1 , 1303 cm −1 and 764 cm −1 ±4 cm −1 .
22. The method of claim 14 , wherein the solid pharmaceutical composition is a capsule.
23. The method of claim 14 , wherein the human suffers from a hyperproliferative disease.
24. The method of claim 14 , wherein the hyperproliferative disease is chronic lymphocytic leukemia.
25. The method of claim 14 , wherein the hyperproliferative disease is small lymphocytic lymphoma.
26. The method of claim 14 , wherein the hyperproliferative disease is mantle cell lymphoma.
27. The method of claim 14 , wherein the hyperproliferative disease is Waldenström's macroglobulinemia.
28. The method of claim 14 , wherein the solid pharmaceutical composition comprises 100 mg of a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin -2-yl)benzamide.